Long acting PLGA complex parenterals and IVIVC development

Event Overview:

This webinar, after a brief presentation on Ascendia’s expertise and capabilities, will focus on poly(lactic-co-glycolic) acid (PLGA), a biocompatible polymer and its application in the development of long-acting injectables (LAI) with insight into the development of in vitro-in vivo correlations (IVIVCs) and in vitro-in vivo relationships (IVIVRs) for complex injectables. A well known speaker on the subject, Dr. Diane Burges, will take a deep dive in PLGA’s chemistry and its drug release phenomenon.

Key Learning Objectives:

Understand Ascendia’s expertise and capabilities
Gain insight into the complexity of PLGA when used to achieve long acting parenteral drug products.
Learn how PLGA polymer complexity affects drug release profiles
Dive into the development of IVIVCs and IVIVRs for complex parenterals

Who Should Attend:

Scientists
Formulators
Managers
Vice Presidents
Chief Scientific Officer

Featured Speakers

Shaukat Ali, PhD

Sr. Director Scientific Affairs and Technical Marketing, Ascendia

Pharmaceutical Solutions

Dr. Shaukat Ali received his PhD from the City University of New York in Chemistry and carried out his postdoc work in Physical Biochemistry at the University of Minnesota and Cornell University. His area of expertise includes liposome, lipid nanoparticles, amorphous solid dispersions, SEEDS, controlled release, and film technologies. He has published over 70 scientific and technical papers and inventor in several US and European patents. Dr. Ali is a member of the editorial advisory boards of American Pharmaceutical Reviews, Biopharma Asia, Contract Pharma, among other journals. Dr. Ali is currently serving as a member of USP Council of expert for the Excipient Test Method Committee (2020-2025). He is the recipient of IPEC Foundation’s Honk de Jong award for his significant contribution in the field of excipient technologies. Dr. Ali is an AAPS Fellow.

Speaker's Email: sali@ascendiacdmo.com

Prof. Diane Burgess, PhD

Pfizer Distinguished Chair of Pharmaceutical Technology

Department of Pharmaceutical Sciences University of Connecticut

Diane Burgess, PhD is the founder of DIANT Pharma (2019). DIANT Pharma develops proprietary continuous manufacturing technology for nanoparticles with a wide array of applications throughout multiple industries, such as lipid nanoparticles and liposomes for pharmaceutical formulations. She is also the Inventor on 14 patents/patent applications—11 of which have been licensed to companies—and five products/product lines have already been commercialized. Her work extends to over 297 refereed publications, over 750 research presentations, over 352 invited presentations, and 30 keynote and plenary addresses.

B.Sc. Pharmacy, University of Strathclyde (1979) and Ph.D. Pharmaceutics, University of London (1984). Fellow of AAPS, CRS, APSTJ, AIMBE and the National Academy of Inventors. 2010 CRS President; 2002 AAPS President. Editor of International Journal of Pharmaceutics (2009 – 2018). Editorial board member of 14 international journals. Recipient of: 2024 NIPTE David J. W. Grant Distinguished Scholar in Basic Pharmaceutics;
2023 AAPS Alice E. Till Advancement of Women in Pharmaceutical Sciences Recognition; 2023 University of Connecticut AAUP Edward C. Marth Mentorship Award; 2018 AAPS Wurster Award in Pharmaceutics; 2014 AAPS Research Achievement Award; 2014 AAPS Outstanding Educator Award; 2014 CRS Distinguished Service Award; 2013 AAPS IPEC Ralph Shangraw Award; 2010 CRSI Fellowship, 2011 APSTJ Nagai International Woman Scientist Award.

Speaker's Email: d.burgess@uconn.edu

For any technical questions please contact Jorge de la Bandera: JdelaBandera@mjhlifesciences.com

Complete this form to enter the webcast. (* indicates required field)

Long acting PLGA complex parenterals and IVIVC development

Wed, Mar 26, 2025 1:30 PM EDT{LOCAL_TZ}

Complete this form to enter the webcast.
(* indicates required field)